Company profile
Verrica Pharmaceuticals Inc.
NASDAQ:VRCABiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Cantharidin | approved | — | 0 | — |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05188729 | phase2 | completed | 2022-02-01 | 2024-04-15 | Verrica Pharmaceuticals Inc. | Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 212905 | NDA | VERRICA PHARMACEUTICALS INC | ||||
Loading… | ||||||